FAQ: Quantum BioPharma's Lucid-MS IND Application and Clinical Trial Progress
Summary
Quantum BioPharma has received final toxicity reports for Lucid-MS, its potential breakthrough Multiple Sclerosis treatment, which will support the company's upcoming IND application to the FDA for a Phase 2 clinical trial.
What is the main announcement from Quantum BioPharma?
Quantum BioPharma has received final reports from its 90-day oral toxicity and toxicokinetic studies for Lucid-MS, which will support the company’s upcoming IND application to the U.S. FDA for a Phase 2 clinical trial.
Why is this development significant for Multiple Sclerosis treatment?
This marks a key milestone in advancing Lucid-MS as a first-in-class treatment targeting demyelination in MS patients, representing a potential breakthrough for treating the underlying mechanism of multiple sclerosis.
What is Lucid-MS and how does it work?
Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, which is the underlying mechanism of multiple sclerosis, in preclinical models.
What is the next step for Quantum BioPharma’s clinical development?
The company will submit an IND application to the U.S. FDA to proceed with a Phase 2 clinical trial for Lucid-MS, using the final toxicity reports to support this application.
What other business interests does Quantum BioPharma maintain?
Quantum BioPharma retains 20.11% ownership of Unbuzzd Wellness Inc. with royalty payments, maintains 100% rights to develop similar products for pharmaceutical uses, and holds strategic investments through its subsidiary FSD Strategic Investments Inc.
Where can investors find more information about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM, and the full press release can be viewed at https://ibn.fm/OCSg0.
What types of disorders does Quantum BioPharma focus on?
Quantum BioPharma is dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.
How does Lucid-MS differ from other MS treatments?
Lucid-MS is positioned as a first-in-class treatment specifically targeting demyelination, the underlying mechanism of multiple sclerosis, rather than just managing symptoms.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 241539